Granted Patent
B2
US 10,829,785 · App. 16/681,964 · Granted Nov 10, 2020
Nucleic acid application primers
Inventors:
Hanna P. Lesch (Kuopio, FI); Kari J. Airenne (Kuopio, FI); Seppo Yla-Herttuala (Kuopio, FI)
Assignee:
Trizell Limited
C12N15/86A61K48/0091C07K14/005C12N7/00A61K48/00C12N2710/14021C12N2710/14043C12N2710/14051C12N2740/15043C12N2740/15051C12N2740/16022C12N2740/16043C12N2740/16045C12N2740/16051C12N2810/6081
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Novel forward primer, reverse primer and poly-linker suitable for replication of nucleic acids in e.g., 293 cells.
Claims (4)
1. A DNA having a sequence selected from SEQ ID No: 1; SEQ ID No: 2; or SEQ ID No: 3.
2. The DNA of claim 1 , the DNA having the sequence of SEQ ID No: 1.
3. The DNA of claim 1 , the DNA having the sequence of SEQ ID No: 2.
4. The DNA of claim 1 , the DNA having the sequence of SEQ ID No: 3.
Assignments (5)
RELEASE OF SECURITY INTEREST
Recorded Jan 31, 2022
From: PHARMACEUTICAL PATENT ATTORNEYS, LLC
To: TRIZELL LTD., F/K/A FINVECTOR LTD. F/K/A ARK THERAPEUTICS LTD.
Reel/Frame 058826/0044 →
CHANGE OF NAME
Recorded Apr 9, 2021
From: FINVECTOR VISION THERAPIES LTD
To: TRIZELL LTD
Reel/Frame 055872/0400 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 9, 2021
From: LESCH, HANNA P.; AIRENNE, KARI J.; YLÄ-HERTTUALA, SEPPO
To: ARK THERAPEUTICS LTD.
Reel/Frame 055872/0405 →
CHANGE OF NAME
Recorded Apr 9, 2021
From: ARK THERAPEUTICS LTD.
To: FINVECTOR VISION THERAPIES LTD
Reel/Frame 055886/0483 →
SECURITY INTEREST
Recorded Nov 19, 2020
From: TRIZELL LTD.
To: PHARMACEUTICAL PATENT ATTORNEYS, LLC
Reel/Frame 054775/0546 →
Priority Claims (1)
GB 0702695.8
· Feb 12, 2007
· national
Continuity (2)
Division
12522646